SCHEDULE: Johnson & Johnson Maintains 15.4% Stake in CVRx
Beneficial Ownership Report Amendment
Johnson & Johnson and its subsidiary, JJDC, Inc., have reported a continued beneficial ownership of 15.4% in CVRx, Inc. common stock.
Summary
- Johnson & Johnson (J&J) and its wholly-owned subsidiary, Johnson & Johnson Innovation JJDC, Inc. (JJDC), jointly filed an Amendment No. 3 to Schedule 13G.
- The filing reports that J&J and JJDC beneficially own an aggregate of 4,024,861 shares of CVRx, Inc. Common Stock.
- This ownership represents 15.4% of CVRx, Inc.'s class of securities.
- The percentage ownership is based on 26,210,109 shares of Common Stock outstanding as of October 30, 2025, as reported in CVRx, Inc.'s Form 10-Q for the period ended September 30, 2025.
- The event requiring this filing occurred on December 31, 2025.
Sentiment
Score: 5
Explanation: This is a factual disclosure of beneficial ownership, which is neutral in sentiment. It reports a continued significant stake by a major institutional investor, without providing new operational or financial performance data.
Positives
- NA
Negatives
- NA
Risks
- This Schedule 13G filing is a disclosure of beneficial ownership and does not contain specific risk factors related to CVRx, Inc.'s operations or financial performance.
Future Outlook
This Schedule 13G filing is a factual disclosure of beneficial ownership and does not contain forward-looking statements or guidance regarding CVRx, Inc.'s future performance or Johnson & Johnson's investment strategy.
Industry Context
This filing indicates that Johnson & Johnson, a major global healthcare company, through its venture capital arm JJDC, maintains a significant strategic stake in CVRx, Inc. Such a substantial holding by a prominent industry player can signal confidence in CVRx's technology or market potential within the medical device or cardiovascular health sector. Schedule 13G filings are routine disclosures for institutional investors holding more than 5% of a company's stock, providing transparency on significant ownership positions.
Comparison to Industry Standards
- NA
Stakeholder Impact
- Shareholders: Provides transparency regarding significant institutional ownership, potentially signaling continued confidence from a major healthcare player in CVRx, Inc.'s long-term prospects.
Key Dates
| Date | Description |
|---|---|
| February 7, 2022 | Initial Schedule 13G filing by the Reporting Persons. |
| February 2, 2024 | Amendment No. 1 to Schedule 13G filed. |
| November 1, 2024 | Amendment No. 2 to Schedule 13G filed. |
| September 30, 2025 | Period end for CVRx, Inc.'s Report on Form 10-Q. |
| October 30, 2025 | Date as of which 26,210,109 shares of Common Stock were outstanding, as reported in CVRx, Inc.'s Form 10-Q. |
| November 6, 2025 | Date CVRx, Inc.'s Report on Form 10-Q for the period ended September 30, 2025, was filed. |
| December 31, 2025 | Date of the event which required the filing of this statement. |
| January 12, 2026 | Signature date for this Amendment No. 3 to Schedule 13G. |
Keywords
CVRx Inc, Johnson & Johnson, JJDC, Beneficial Ownership, Schedule 13G, Common Stock, Institutional Investor, Healthcare Investment
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.